LFCR

Lifecore Biomedical Inc

Add to Watchlist

Advanced Chart

7.930

+0.23(2.987%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

7.950

Open

7.920

VWAP

7.84

Vol

101.18K

Mkt Cap

293.62M

Low

7.750

Amount

793.37K

EV/EBITDA(TTM)

Total Shares

30.55M

449.94M

EV/OCF(TTM)

P/S(TTM)

2.08

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

FY2026Q2

FY2026Q1

36.47M

+3.75%

-0.110

-41.93%

33.25M

+2.11%

-0.140

-30.35%

25.25M

+2.21%

-0.290

-22.52%

Estimates Revision

The market is revising Upward the revenue expectations for Lifecore Biomedical, Inc. (LFCR) for FY2026, with the revenue forecasts being adjusted by 0.97% over the past three months. During the same period, the stock price has changed by 18.18%.

Revenue Estimates for FY2026

Revise Upward

+0.97%

In Past 3 Month

EPS Estimates for FY2026

Revise Downward

-23.77%

In Past 3 Month

Stock Price

Go Up

+18.18%

In Past 3 Month

5 Analyst Rating

10.34% Upside

Wall Street analysts forecast LFCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFCR is 8.75 USD with a low forecast of 7.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

3 Hold

0 Sell

Moderate Buy

10.34% Upside

Current: 7.930

Low

7.50

Averages

8.75

High

10.00

10.34% Upside

Current: 7.930

Low

7.50

Averages

8.75

High

10.00

KeyBanc

Sector Weight

initiated

2025-09-04

Reason

KeyBanc

Price Target

2025-09-04

initiated

Sector Weight

Reason

KeyBanc initiated coverage of Lifecore with a Sector Weight rating and no price target. While the shares trade at a a "relatively modest" multiple, meaningful valuation expansion will require new program wins or contractual step-ups, the analyst tells investors in a research note. The firm says Lifecore's pipeline is transitioning to faster growing markets.

William Blair

Outperform

initiated

2025-05-21

Reason

William Blair

Price Target

2025-05-21

initiated

Outperform

Reason

William Blair initiated coverage of Lifecore (LFCR) with an Outperform rating. Minimum volume commitments from Alcon (ALC) represent "a solid foundation for Lifecore's achievable midterm revenue guide," says the analyst, who projects revenue will grow at an 11.6% compound annual rate from FY25 to FY28, consistent with Lifecore's guidance.

Stephens & Co.

Jacob Johnson

Hold

Reiterates

2025-01-03

Reason

Stephens & Co.

Jacob Johnson

Price Target

2025-01-03

Reiterates

Hold

Reason

Craig-Hallum

Matthew Hewitt

Strong Buy

Maintains

$8 → $10

2024-11-22

Reason

Craig-Hallum

Matthew Hewitt

Price Target

$8 → $10

2024-11-22

Maintains

Strong Buy

Reason

Craig-Hallum analyst Matthew Hewitt raised the firm's price target on Lifecore to $10 from $8 and keeps a Buy rating on the shares. Lifecore's investor day was successful, with management showcasing the company's 5-head filler capabilities and the strong demand for its business, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Lifecore Biomedical Inc (LFCR.O) is -16.56, compared to its 5-year average forward P/E of -61.18. For a more detailed relative valuation and DCF analysis to assess Lifecore Biomedical Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-61.18

Current PE

-16.56

Overvalued PE

238.46

Undervalued PE

-360.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

23.16

Current EV/EBITDA

21.31

Overvalued EV/EBITDA

41.84

Undervalued EV/EBITDA

4.47

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued

5Y Average PS

1.57

Current PS

2.22

Overvalued PS

2.08

Undervalued PS

1.06

Financials

Annual

Quarterly

FY2025Q4

YoY :

-3.81%

36.44M

Total Revenue

FY2025Q4

YoY :

-51.56%

2.90M

Operating Profit

FY2025Q4

YoY :

-83.81%

-1.15M

Net Income after Tax

FY2025Q4

YoY :

-73.91%

-0.06

EPS - Diluted

FY2025Q4

YoY :

-45.86%

3.25M

Free Cash Flow

FY2025Q4

YoY :

-15.84%

38.37

Gross Profit Margin - %

FY2025Q4

YoY :

-25.25%

-10.57

FCF Margin - %

FY2025Q4

YoY :

-83.16%

-3.15

Net Margin - %

FY2025Q4

YoY :

-100.00%

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

9.9M

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

97.6K

USD

Months

0-12

1.2M

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

9.9M

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

97.6K

USD

Months

0-12

1.2M

USD

Months

LFCR News & Events

Events Timeline

2025-06-17 (ET)

2025-06-17

07:19:42

Lifecore signs new 10-year commercial manufacturing, supply agreement

2025-06-12 (ET)

2025-06-12

07:08:17

Lifecore receives accelerated payment of $10M in proceeds from equipment sale

2025-05-27 (ET)

2025-05-27

07:08:45

Lifecore names Mark DaFonseca as Chief Commercial Officer

News

4.0

09-04Benzinga

Keybanc Begins Coverage of Lifecore Biomedical with a Sector Weight Rating

7.0

08-14Globenewswire

LIFECORE ALERT: Bragar Eagel & Squire, P.C. is Investigating LifeCore Biomedical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

7.5

06-18NASDAQ.COM

Lifecore Signs 10-Year Manufacturing Deal To Support Novel Ophthalmic Therapy